Imatinib treatment: Specific issues related to safety, fertility, and pregnancy

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 21-25

  Hensley, Martee L ^b   Ford, John M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CYTARABINE; IMATINIB; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ASCITES; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ECCHYMOSIS; EDEMA; EPISTAXIS; EXFOLIATIVE DERMATITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLAUCOMA; GYNECOMASTIA; HEADACHE; HERPES ZOSTER; HUMAN; HYPOKALEMIA; INFLUENZA; INSOMNIA; LIVER TOXICITY; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MALE FERTILITY; MENSTRUATION DISORDER; MUSCLE CRAMP; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; PERICARDIAL EFFUSION; PETECHIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; RIGOR; SEIZURE; SORE THROAT; SPERMATOGENESIS; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT GAIN; BLOOD DISEASE; DRUG EFFECT; FERTILITY; PATHOLOGY; PREGNANCY OUTCOME; REVIEW;

CLINICAL TRIALS; FEMALE; FERTILITY; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; PIPERAZINES; PREGNANCY; PREGNANCY OUTCOME; PYRIMIDINES;

EID: 0037497262     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50038     Document Type: Conference Paper

References (11)

1. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
2. Buchdunger E, Zimmerman J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phinylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
3. Cancer Therapy Evaluation Program: Common Toxicity Criteria, version 2.0. CDTD, NCI, NIH, DHSS. March 1998 (http://ctep.info.nih.gov/ctc3.htm)
4. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
5. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
6. Druker BJ, Talpaz M, Resta DJ, et al: Clinical efficacy and safety of an abl-specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
7. Heinrich MC, Griffith JD, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
8. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
9. Okuda K, Weisberg E, Gilliland DG, et al: ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448, 2001
10. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539, 2002
11. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase II study. Blood 99:1928-1937, 2002